TNFRSF17 and Miyoshi myopathy: In a single-center retrospective study on relapsed and refractory MM, 11 out of 78 patients (14.1%) treated with B-cell maturation antigen (BCMA)-targeted CAR-T therapy experienced cardiovascular AEs, a rate comparable to those observed in CD19-targeted CAR-T therapy.